Tcr2 Therapeutics - TCRR STOCK NEWS

TCR² Therapeutics (Nasdaq: TCRR) announced the e-poster presentation of new preclinical data at the AACR Virtual Special Conference on Tumor Immunology and Immunotherapy (October 5-6, 2021). The e-poster details their IL-15 Receptor Fusion Protein that enhances TRuC-T cells' persistence, showcasing improvements in T cell proliferation and survival. In animal models, IL-15 co-expression resulted in significant tumor cell clearance. TCR² aims to optimize TRuC-T cells for better efficacy against solid tumors and will discuss strategies at the upcoming R&D Day on October 20.

TCR² Therapeutics announced positive interim results from the gavo-cel Phase 1/2 clinical trial targeting mesothelin-expressing solid tumors. The overall response rate (ORR) was 31%, with an impressive disease control rate (DCR) of 81% in 16 evaluable patients. Tumor regression was observed in 94% of patients, and the median overall survival for those with refractory mesothelioma was 11.2 months. Gavo-cel was well tolerated, with manageable adverse events. The trial is ongoing, with a focus on refining the recommended Phase 2 dose (RP2D) to optimize patient outcomes.

TCR² Therapeutics Inc. (TCRR) announced a conference call on September 17, 2021, to discuss extended data from its ongoing Phase 1 clinical trial of gavo-cel for mesothelin-expressing solid tumors. This data, to be presented at the European Society for Medical Oncology Congress, involves 17 evaluable patients and focuses on three cancer types: malignant mesothelioma, ovarian cancer, and cholangiocarcinoma. The event will include clinical and translational insights, and a replay will be available on their website for 30 days post-event.

TCR2 Therapeutics, a clinical-stage company focused on novel T cell therapies for cancer, announced that CFO Ian Somaiya will present an update on the company's progress at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM E.T. The presentation will be available through a live webcast on the company's investor website, with an archived replay accessible for 30 days. TCR2 is developing TRuC-T cells, which have shown superior anti-tumor activity in preclinical studies and are currently in clinical trials targeting multiple cancers.

TCR² Therapeutics Inc. (Nasdaq: TCRR) has received Orphan Drug Designation from the FDA for its cell therapy gavo-cel aimed at treating cholangiocarcinoma. The company will present new clinical data on gavo-cel's efficacy in mesothelin-expressing solid tumors during an upcoming conference on September 17. This includes findings on malignant mesothelioma, ovarian cancer, and cholangiocarcinoma. Gavo-cel is part of TCR²'s clinical-stage pipeline, targeting patients with various solid tumors.

TCR² Therapeutics announced the appointment of Dr. Priti Hegde to its Board of Directors, effective August 26, 2021. Dr. Hegde, with over 20 years in cancer genomics and clinical product development, will enhance TCR²'s focus on clinical trials and cancer patient responses. Former board member Patrick Baeuerle steps down effective August 24, 2021, but will remain in an advisory role. TCR² is advancing its lead product candidate, gavo-cel, in clinical trials aimed at treating solid tumors, leveraging Dr. Hegde's expertise for better clinical assay designs.

TCR2 Therapeutics Inc. (Nasdaq: TCRR) announced an interim update on its Phase 1/2 clinical trial of gavo-cel, which will be featured at the European Society for Medical Oncology (ESMO) Congress on September 17, 2021. The data will include results from at least 17 evaluable patients with refractory mesothelin-expressing solid tumors. TCR2 has opted out of a poster presentation at the World Conference on Lung Cancer, leading to the withdrawal of its abstract. CEO Garry Menzel expressed anticipation regarding the potential of gavo-cel as a leading therapy for mesothelin-directed treatments.

TCR2 Therapeutics (Nasdaq: TCRR) announced its Q2 2021 results and updates on its gavo-cel Phase 1 trial. The company plans to present new clinical data at the European Society of Medical Oncology Congress on September 17, including insights from 17 patients. TCR2 reported a net loss of $24.3 million for Q2 2021, up from $16.2 million a year earlier, with R&D expenses increasing to $18.6 million. The company ended Q2 with $317.3 million in cash and projects net cash use between $100-110 million for 2021. They aim to select a recommended Phase 2 dose for gavo-cel by year-end.

TCR² Therapeutics has appointed Peter Olagunju as its new Chief Technical Officer. With over 20 years of experience in cell and gene therapy, he will manage key areas such as process development and manufacturing. His prior roles include Senior Vice President at FerGene Inc. and Vice President at bluebird bio, where he contributed to significant gene therapy projects. This leadership addition comes as TCR² scales its cGMP manufacturing capacity for upcoming clinical trials, including a Phase 2 trial for gavo-cel targeting solid tumors.